Mirae Asset Global Etfs Holdings Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 69,354 shares of ARQT stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,354
Previous 69,369
0.02%
Holding current value
$1.02 Million
Previous $645,000
49.77%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ARQT
# of Institutions
218Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$182 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$168 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$161 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$129 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$127 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $886M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...